Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions
Alberto Martini(The University of Texas MD Anderson Cancer Center), Elio Mazzone(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Giorgio Gandaglia(Vita-Salute San Raffaele University), Giancarlo Marra(Royal Free London NHS Foundation Trust), Junlong Zhuang(Nanjing Drum Tower Hospital), Paolo Gontero(Fondazione Ricerca Molinette), Hongqian Guo(Nanjing Drum Tower Hospital), G. Ploussard(Institut universitaire du cancer de Toulouse Oncopole), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Jean‐Baptiste Beauval, M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Roderick C. N. van den Berg(St. Antonius Ziekenhuis), Andrea Minervini(Azienda Ospedaliero-Universitaria Careggi), Massimo Valério(University Hospital of Geneva), Riccardo Campi(University of Florence), Timo Soeterik(St. Antonius Ziekenhuis), Alae Touzani(Lyon Genou Centre Albert Trillat), Francesco Montorsi(Vita-Salute San Raffaele University)
Cited by 10
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532